Polymarket Market
Prediction market
Track current outcome prices, market depth, volume, liquidity, and recent trades for Prediction market.
Upcoming
- Probability
- Unavailable
Outcomes
Market outcomes
Live pricing
Pricing and liquidity
Current bid, ask, midpoint, spread, and market depth for this outcome.
- Best bid
- Unavailable
- Best ask
- Unavailable
- Midpoint
- Unavailable
- Spread
- Unavailable
- Last trade
- Unavailable
- Depth
- Unavailable
Price history
Waiting for price history
History unavailable
Bids
| Price | Size |
|---|
Asks
| Price | Size |
|---|
Trades
Recent trades
Latest visible trades for this market.
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99.9% 20 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99.9% 20 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99.9% 20 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99.9% 20 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99.9% 20 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99.9% 167 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 99% 42.8 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 90% 73.2 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 89.9% 42.8 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 75% 12 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?No 27.6% 31.21 shares
- FDA approves Telix Pharmaceuticalsâ TLX250-CDx for kidney cancer imaging?Yes 74% 56.09 shares